Shimizu, T.; Miyake, M.; Hori, S.; Ichikawa, K.; Omori, C.; Iemura, Y.; Owari, T.; Itami, Y.; Nakai, Y.; Anai, S.;
et al. Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. Diagnostics 2020, 10, 310.
https://doi.org/10.3390/diagnostics10050310
AMA Style
Shimizu T, Miyake M, Hori S, Ichikawa K, Omori C, Iemura Y, Owari T, Itami Y, Nakai Y, Anai S,
et al. Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. Diagnostics. 2020; 10(5):310.
https://doi.org/10.3390/diagnostics10050310
Chicago/Turabian Style
Shimizu, Takuto, Makito Miyake, Shunta Hori, Kazuki Ichikawa, Chihiro Omori, Yusuke Iemura, Takuya Owari, Yoshitaka Itami, Yasushi Nakai, Satoshi Anai,
and et al. 2020. "Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab" Diagnostics 10, no. 5: 310.
https://doi.org/10.3390/diagnostics10050310
APA Style
Shimizu, T., Miyake, M., Hori, S., Ichikawa, K., Omori, C., Iemura, Y., Owari, T., Itami, Y., Nakai, Y., Anai, S., Tomioka, A., Tanaka, N., & Fujimoto, K.
(2020). Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. Diagnostics, 10(5), 310.
https://doi.org/10.3390/diagnostics10050310